Irinotecan Plus Doxorubicin Hydrochloride Liposome for Relapsed or
Refractory Wilms Tumor
Purpose: The prognosis of the relapsed or refractory Wilms tumor (R/R
WT) was dismal and new salvage chemotherapy was needed. This study aimed
to evaluate the efficacy of the combination of irinotecan and
doxorubicin hydrochloride liposome regimen (AI) for R/R WT. Methods: The
present study enrolled the R/R WT who were treated with AI regimen at
Sun Yat-Sen University Cancer Center from July 2018 to September 2020.
The response was defined as the best observed response after the last
two cycle and toxicity was evaluated. Result: Total of 16 patients with
median age of 4.2 years (0.5 to 11 years) were enrolled, including 14
patients with relapsed disease and 2 patients with refractory disease.
These patients received 1 to 8 courses (median 3 courses).14 patients
were assessable for response: 2 complete response (CR), 5 partial
response (PR), 2 stable disease (SD), 5 progression disease (PD). The
objective response rate was 50% (2 CR, 5 PR) and the disease control
rate was 64% (2 CR, 5 PR, and 2 SD). The median progression-free
survival was 3.5 months (range 0.5-12 months), and the median survival
duration was 8 months (range 1-28 months). Sixteen patients were
assessable for toxicity, with most common grade 3 or 4 adverse events
were alopecia (62%), leucopenia (40%), abdominal pain (38%), etc. No
fatal adverse events have been observed. Conclusion: The AI regimen has
positive efficacy with tolerated toxicity, it may provide an alternative
option for the treatment of R/R WT.